预约演示
Fierce Pharma Asia—Pfizer's eye for China ADC deals; Astellas' gastric cancer rejection
临床3期
Pfizer's ADC prowl, Astellas' gastric cancer rejection and details of Takeda's 2022 TYK2 buy made our news this week.
As Pfizer continues itSeagenl for antPfizerdrug conjugate (ADCs) dealsADChe company is keeping an eye on opportunities around the globe. In an interview, Pfizer’s new oncology chief Chris Boshoff, Ph.D., said the company is looking for opportunities in China, which he said "is important in this whole area, especially ADC development." The company is “not currently looking for big acquisitions,” Boshoff added.
AftAstellasnggastric cancerrials, Astellas’ near-tFDA approval ambitions for its zolbetuximab have been dashed because of manufacturing issues. The FDA sent the company a complete response letter after flagging unresolved deficiencies at a third-party manufacturing facility during a prelicense inspection.
3. JPM24: How Takeda beat 'almost Astellasopharmaceutical company' to win Nimbus’zolbetuximabFDA
Takeda scooped up a potential rival to Bristol Myers Squibb’s Sotyktu whenNimbusreTYK2wn $4 billion for Nimbus Therapeutics’ tyrosine kinase 2 med, now known as TAK-279, in 2022. In an interview on the sidelines of this year’s J.P. Morgan Healthcare Conference, Takeda's head of R&D, Andy Plump, M.D., Ph.D., revealed just how competitive the process was. At some point “almost every biopharmaceutical company” was vying for the asset, Plump said. Takeda won out after interacting with Nimbus for a “couple of years” and Plump says those relationships were one of the reasons it ultimately won out.
4. Next-gen Lilly obesity drug secures Bristol Myers Squibbent readies Chinese approval pushNimbus Therapeuticstyrosine kinase 2TAK-279Nimbus
Innovent is Lillynobesity to heat up China’s obesity mInnoventth a phase 3 win for its mazdutide. The Chinese biotech bought the rights to the dual GLP-1/glucagon receptor agonist from Eli Lilly in 2019 for an undisclosed sum. Now, the deal is paying off with new data from a late-stage clinical trial, which hit both of its primary endpoints by week 32. The company is now preparing its first drug new drug application.
Innovent heats up hot flash rivalry, hitting obesity goals to stay on Astellas’ heelsmazdutideChinese biotechGLP-1/glucagon receptor agonistGLP-1/glucagon receptorEli Lilly
Bayer is hot on Astellas’ tail with its hot flash candidate elinzanetant, which met all four endpoints across two phase 3 studies. Astellas’ rival med Veozah scored approval last year, but Bayer’s could become a worthy competitor. The detailed data from Bayer’s studies will be shared at upcoming scientific congresses, the company said.
With a new Singapore outpost, Flagship is taking its time to understand the “Chinese biotech innovation ecosystem” before making any moves in China, CEO Naubar Afeyan, Ph.D., said in an interview on the sidelines of this year’s J.P. Morgan Healthcare Conference. The firm is active in Japan and South Korea after going global with its London and Singapore offices, and it just inked a deal with Samsung that includes access to clinical samples and investment in Flagship firms.
ChiWuXi BiologicsecWuXi AppTeced two peptide manufacturing plants in order to meet high demand for peptide therapeutics. The new digs will make for the company’s third peptide manufacturing plant in Changzhou and its first in Taixing. Together, the facilities will boost WuXi AppTec’s total reactor volume to 32,000 liters. Meanwhile, WuXi Biologics is expanding its new site in Worcester, Massachusetts, to meet growing demand.
8. Athersys files for bankruptcy, sells assets to Healios in wake of stroke cell therapy’s struggles
10.Boehringer Ingelheimts powder dry, pays WuXi $20M for 2 prKyowa Kirinonoclonal antibodies
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。